Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 361-370

  Udall, Margarita ^a   Harnett, James ^a   Mardekian, Jack ^a  

^a PFIZER INC   (United States)

Author keywords

Costs; Gabapentin; Painful diabetic peripheral neuropathy; Pregabalin; Resource utilization

Indexed keywords

ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DATA BASE; DIABETIC NEUROPATHY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; PRESCRIPTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AMINES; ANALGESICS; CYCLOHEXANECARBOXYLIC ACIDS; DATABASES, FACTUAL; DIABETIC NEPHROPATHIES; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PAIN; PRESCRIPTION FEES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84858144604     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.650773     Document Type: Article

References (30)

1. Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24 (Pubitemid 23121981)
2. Davies M, Brophy S, Williams R, et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-22 (Pubitemid 44127574)
3. Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, post-herpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008;8:45-56
4. Benbow SJ, Wallymahmed ME, Macfarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med 1998;91:733-7 (Pubitemid 28508618)
5. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47:123-8 (Pubitemid 30009719)
6. Gore M, Brandenburg N, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374-85 (Pubitemid 41527124)
7. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006;20:26-33 (Pubitemid 43028410)
8. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med 2007;49:672-9 (Pubitemid 46918860)
9. Gore M, Brandenburg N, Hoffman D, et al. Burden of illness in painful diabetic peripheral neuropathy (DPN): the patients' perspective. J Pain 2006; 7:892-900 (Pubitemid 44854739)
10. Ritzwoller DP, Ellis JL, Korner EJ, et al. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr Med Res Opin 2009;25:1319-28
11. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010;11:360-8
12. Dworkin RH, Panarites CJ, Armstrong EP, et al. Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy. J Am Geriatr Soc 2011;59:827-36
13. Dibonaventura MD, Cappelleri JC, Joshi AV. Association between pain severity and health care resource use, health status, productivity and related costs in painful diabetic peripheral neuropathy patients. Pain Med 2011; 12:799-807
14. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34 (Pubitemid 37443116)
15. Dworkin RH, O'connor PW, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132:237-51 (Pubitemid 350051570)
16. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clinic Proc 2006;81:S12-25
17. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69 (Pubitemid 44581463)
18. Finnerup N, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305 (Pubitemid 41752987)
19. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;11:153-62 (Pubitemid 38373032)
20. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21 (Pubitemid 46744774)
21. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65
22. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care 2009;15:e95-102
23. Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care 2010;16:447-56
24. American Society of Pain Educators. Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract 2006;(Suppl):3-19
25. Gore M, Tai KS, Zlateva G, et al. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract 2011; 11:528-39
26. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
27. D'Agostino Jr RB,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-81 (Pubitemid 28466823)
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9
29. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2007;62:76-87
30. Perez C, Navarro A, Saldana MT, et al. Pregabalin and gabapentin in peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther 2010;32:1357-70